LEO Pharma Inc. Announced New TaclonexÂ® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% Indication for Treatment of Scalp Plaque Psoriasis in Pediatric Patients Ages 12-17